HCA Is Down 26% in 160 Days. What History Suggests.

HCA Healthcare Is Down 26% in 160 Days. What History Suggests.

While headline narratives focus on C-suite changes and minor daily fluctuations, the underlying data reveals a much more significant shift in momentum. HCA Healthcare, Inc. (HCA) is down 26% from its all-time high as of September 2, 2026, and has been falling for approximately 160 days. The Drawdown Severity Score™ stands at 5.3, placing it in the red zone with a Strong rating. In 6 comparable prior drops of this depth, the stock took an average of 427 days to recover.

What the Mainstream Narrative Misses About HCA

Recent financial headlines paint a mixed but generally optimistic picture of the hospital operator. Simply Wall St reports that the stock still looks cheap given its earnings power, while Yahoo Finance highlights that Wall Street analysts continue to favor the company. Additionally, regulatory filings tracked by Stock Titan show recent insider transactions, and MarketBeat reports that Royal London Asset Management Ltd. recently acquired a new stake in the company.

However, focusing solely on these isolated events overlooks the structural shift in the stock's price action. Our data shows that HCA has transitioned from the yellow zone to the red zone, indicating a deeper and more persistent trend than a standard market pullback. While the mainstream narrative treats this as a temporary bump, our Drawdown Severity Score™ of 5.3 suggests that the current correction has entered a historically significant phase.

Hospital operators often experience lagging indicators of economic stress, which can take months to reflect in earnings reports. While analysts look at backward-looking quarterly filings, the market has already begun repricing the stock's risk profile. This divergence between optimistic analyst sentiment and negative price momentum is a common feature of deep drawdown events.

The Data Reality: Severity Scores and Historical Context

The transition of HCA into the red zone is not an arbitrary label. It is based on a quantitative assessment of the stock's current price relative to its historical behavior. The current price of $402.06 represents a -26.2% drawdown from the all-time high of $545.13.

This -26.2% decline is far from the asset's typical behavior. Across 148 total historical drawdown events in our database, the average max drawdown for HCA is only -5.0%. Furthermore, the average drawdown duration is just 35 days, making the current 160-day stretch an extreme outlier.

When a stock exceeds its average historical drawdown by such a wide margin, it indicates that the underlying market dynamics have fundamentally changed. A 35-day average drawdown suggests that HCA typically recovers quickly from minor setbacks. The fact that the current drawdown has lasted 160 days indicates that the selling pressure is persistent and structurally different from past minor pullbacks.

Historical Precedent: Past Red Zone Drops

To understand where HCA might go next, we must look at how it behaved during similar historical events. Our database shows that HCA has experienced a drawdown of 25% or worse only 6 times in its history.

These deep drawdowns are rare, but when they occur, they tend to be prolonged. The average duration of these comparable drops is 427 days. This historical average is nearly triple the current 160 days that the stock has spent in its current drawdown, suggesting that recoveries of this magnitude require patience.

Looking at the historical distribution of these drawdowns provides essential context for risk management. In all 6 prior instances where HCA dropped by 25% or more, the path to recovery was characterized by extended consolidation periods. The stock did not instantly rebound, but rather spent months forming a base before climbing back to its previous highs.

Valuation Context and Historical Percentiles

To place this price decline in context, we examine where the company's valuation multiples sit relative to its own history. As of 2026-08-31, HCA's Price-to-Sales (P/S) ratio was 1.2, which sits in the 74th percentile of its own daily history since 2011-03-10, placing it above its typical historical range and its historical median of 0.91. Meanwhile, its EV-to-EBITDA (EV/EBITDA) ratio stood at 8.9, placing it in the 66th percentile of its daily historical record since 2011-03-10, which is within its typical historical range and slightly above its historical median of 8.4.

This valuation framing shows that despite a 26.2% drop in share price, the stock's multiples have not fallen to historically low levels. The P/S ratio remains in the upper quartile of its historical distribution, reflecting that sales growth expectations or actual sales levels have adjusted alongside the price. Understanding these percentiles helps clarify that a deep price drop does not automatically translate to historically cheap valuation multiples.

The News Narrative vs. Statistical Reality

There is a clear divergence between the fundamental stories circulating in the media and the technical reality of the stock's price chart. For instance, TechStock² reported that HCA shares dipped 0.5% as layoffs coincided with a $400 million payer mix impact. While a 0.5% daily move seems negligible, the compounding effect of these fundamental pressures has contributed to the broader 160-day decline.

Additionally, MarketWatch noted that HCA underperformed its competitors on a recent Thursday. While daily relative strength is a common focus for short-term traders, the long-term trend is what matters for risk management. The shift to a Drawdown Severity Score™ of 5.3 indicates that the selling pressure is systemic rather than a one-day anomaly.

The company is also navigating internal changes, such as those reported by The Business Journals regarding updates to its C-suite. While leadership transitions can sometimes spark optimism, the historical data suggests that structural price recoveries take time to materialize. Executive changes often signal a period of operational transition, which can introduce new variables for investors to consider.

Furthermore, the $400 million payer mix impact highlighted by TechStock² represents a tangible operational headwind. In the healthcare sector, shifts in payer mix, such as a higher proportion of government-insured or uninsured patients, directly impact operating margins. The historical data shows that when these operational headwinds align with a red zone Drawdown Severity Score™, the recovery process is rarely swift.

What the Data Can and Cannot Tell You

Our Drawdown Severity Score™ is a quantitative tool designed to measure risk, not a predictive crystal ball. It tells us that a 26.2% drawdown is a rare and historically significant event for HCA, occurring only 6 times prior. It also tells us that past recoveries from this depth have historically taken over a year on average.

What the data cannot do is predict the exact day the bottom will be reached. External factors, such as shifting healthcare regulations, broader macroeconomic trends, or unexpected earnings surprises, can always alter the recovery timeline. Investors should use these metrics as a framework for assessing risk tolerance rather than a definitive forecast of future price action.

By focusing on the historical frequency and duration of these events, we can strip away the emotional noise of daily market commentary. The data provides a sober reminder that deep corrections are a normal, if painful, part of an asset's long-term lifecycle. Monitoring the severity score as it evolves helps investors track whether the selling pressure is stabilizing or continuing to intensify.